Business Context and Reporting Period
This Form 8-K is a current report filed by REGENXBIO Inc. (RGNX) on March 14, 2022. The filing addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Event: Daniel J. Abdun-Nabi notified the Company he will not stand for re-election as a director.
- Timing: His current term expires at the Company's 2022 annual meeting of stockholders.
- Reason: The departure is not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No new risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investors to Verify
- Confirm the date of the 2022 annual meeting of stockholders to determine the exact expiration of Mr. Abdun-Nabi's term.
- Verify if the Board has initiated a search for a replacement director to fill the vacancy upon the term's expiration.
- Review the Company's proxy statement for the 2022 annual meeting for details on the remaining director slate.